<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.molecularbrain.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Molecular Brain - Latest Articles</title>
        <link>http://www.molecularbrain.com</link>
        <description>The latest research articles published by Molecular Brain</description>
        <dc:date>2013-05-14T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.molecularbrain.com/content/6/1/24" />
                                <rdf:li rdf:resource="http://www.molecularbrain.com/content/6/1/23" />
                                <rdf:li rdf:resource="http://www.molecularbrain.com/content/6/1/22" />
                                <rdf:li rdf:resource="http://www.molecularbrain.com/content/6/1/19" />
                                <rdf:li rdf:resource="http://www.molecularbrain.com/content/6/1/21" />
                                <rdf:li rdf:resource="http://www.molecularbrain.com/content/6/1/20" />
                                <rdf:li rdf:resource="http://www.molecularbrain.com/content/6/1/18" />
                                <rdf:li rdf:resource="http://www.molecularbrain.com/content/6/1/17" />
                                <rdf:li rdf:resource="http://www.molecularbrain.com/content/6/1/16" />
                                <rdf:li rdf:resource="http://www.molecularbrain.com/content/6/1/15" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.molecularbrain.com/content/6/1/24">
        <title>Acute 5-HT7 receptor activation increases NMDA-evoked currents and differentially alters NMDA receptor subunit phosphorylation and trafficking in hippocampal neurons</title>
        <description>Background:
N-methyl-D-aspartate (NMDA) receptors are regulated by several G protein-coupled receptors (GPCRs) as well as receptor tyrosine kinases. Serotonin (5-HT) type 7 receptors are expressed throughout the brain including the thalamus and hippocampus. Long-term (2--24 h) activation of 5-HT7 receptors promotes the expression of neuroprotective growth factor receptors, including the platelet-derived growth factor (PDGF) beta receptors which can protect neurons against NMDA-induced neurotoxicity.
Results:
In contrast to long-term activation of 5-HT7 receptors, acute (5 min) treatment of isolated hippocampal neurons with the 5-HT7 receptor agonist 5-carboxamidotryptamine (5-CT) enhances NMDA-evoked peak currents and this increase in peak currents is blocked by the 5-HT7 receptor antagonist, SB 269970. In hippocampal slices, acute 5-HT7 receptor activation increases NR1 NMDA receptor subunit phosphorylation and differentially alters the phosphorylation state of the NR2B and NR2A subunits. NMDA receptor subunit cell surface expression is also differentially altered by 5-HT7 receptor agonists: NR2B cell surface expression is decreased whereas NR1 and NR2A surface expression are not significantly altered.
Conclusions:
In contrast to the negative regulatory effects of long-term activation of 5-HT7 receptors on NMDA receptor signaling, acute activation of 5-HT7 receptors promotes NMDA receptor activity. These findings highlight the potential for temporally differential regulation of NMDA receptors by the 5-HT7 receptor.</description>
        <link>http://www.molecularbrain.com/content/6/1/24</link>
                <dc:creator>Maryam Vasefi</dc:creator>
                <dc:creator>Kai Yang</dc:creator>
                <dc:creator>Jerry Li</dc:creator>
                <dc:creator>Jeff Kruk</dc:creator>
                <dc:creator>John Heikkila</dc:creator>
                <dc:creator>Michael Jackson</dc:creator>
                <dc:creator>John MacDonald</dc:creator>
                <dc:creator>Michael Beazely</dc:creator>
                <dc:source>Molecular Brain 2013, null:24</dc:source>
        <dc:date>2013-05-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6606-6-24</dc:identifier>
                                <prism:require>/content/figures/1756-6606-6-24-toc.gif</prism:require>
                <prism:publicationName>Molecular Brain</prism:publicationName>
        <prism:issn>1756-6606</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>24</prism:startingPage>
        <prism:publicationDate>2013-05-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularbrain.com/content/6/1/23">
        <title>An unexpected role of neuroligin-2 in regulating KCC2 and GABA functional switch</title>
        <description>Background:
GABAA receptors are ligand-gated Cl- channels, and the intracellular Cl- concentration governs whether GABA function is excitatory or inhibitory. During early brain development, GABA undergoes functional switch from excitation to inhibition: GABA depolarizes immature neurons but hyperpolarizes mature neurons due to a developmental decrease of intracellular Cl- concentration. This GABA functional switch is mainly mediated by the up-regulation of KCC2, a potassium-chloride cotransporter that pumps Cl- outside neurons. However, the upstream factor that regulates KCC2 expression is unclear.
Results:
We report here that KCC2 is unexpectedly regulated by neuroligin-2 (NL2), a cell adhesion molecule specifically localized at GABAergic synapses. The expression of NL2 precedes that of KCC2 in early postnatal development. Upon knockdown of NL2, the expression level of KCC2 is significantly decreased, and GABA functional switch is significantly delayed during early development. Overexpression of shRNA-proof NL2 rescues both KCC2 reduction and delayed GABA functional switch induced by NL2 shRNAs. Moreover, NL2 appears to be required to maintain GABA inhibitory function even in mature neurons, because knockdown NL2 reverses GABA action to excitatory. Gramicidin-perforated patch clamp recordings confirm that NL2 directly regulates the GABA equilibrium potential. We further demonstrate that knockdown of NL2 decreases dendritic spines through down-regulating KCC2.
Conclusions:
Our data suggest that in addition to its conventional role as a cell adhesion molecule to regulate GABAergic synaptogenesis, NL2 also regulates KCC2 to modulate GABA functional switch and even glutamatergic synapses. Therefore, NL2 may serve as a master regulator in balancing excitation and inhibition in the brain.</description>
        <link>http://www.molecularbrain.com/content/6/1/23</link>
                <dc:creator>Chicheng Sun</dc:creator>
                <dc:creator>Lei Zhang</dc:creator>
                <dc:creator>Gong Chen</dc:creator>
                <dc:source>Molecular Brain 2013, null:23</dc:source>
        <dc:date>2013-05-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6606-6-23</dc:identifier>
                                <prism:require>/content/figures/1756-6606-6-23-toc.gif</prism:require>
                <prism:publicationName>Molecular Brain</prism:publicationName>
        <prism:issn>1756-6606</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>23</prism:startingPage>
        <prism:publicationDate>2013-05-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularbrain.com/content/6/1/22">
        <title>Dock3 interaction with a glutamate-receptor NR2D subunit protects neurons from excitotoxicity</title>
        <description>Background:
N-methyl-D-aspartate receptors (NMDARs) are critical for neuronal development and synaptic plasticity. Dysregulation of NMDARs is implicated in neuropsychiatric disorders. Native NMDARs are heteromultimeric protein complexes consisting of NR1 and NR2 subunits. NR2 subunits (NR2A&#8211;D) are the major determinants of the functional properties of NMDARs. Most research has focused on NR2A- and/or NR2B-containing receptors. A recent study demonstrated that NR2C- and/or NR2D-containing NMDARs are the primary targets of memantine, a drug that is widely prescribed to treat Alzheimer&#8217;s disease. Our laboratory demonstrated that memantine prevents the loss of retinal ganglion cells (RGCs) in GLAST glutamate transporter knockout mice, a model of normal tension glaucoma (NTG), suggesting that NR2D-containing receptors may be involved in RGC loss in NTG.
Results:
Here we demonstrate that NR2D deficiency attenuates RGC loss in GLAST-deficient mice. Furthermore, Dock3, a guanine nucleotide exchange factor, binds to the NR2D C-terminal domain and reduces the surface expression of NR2D, thereby protecting RGCs from excitotoxicity.
Conclusions:
These results suggest that NR2D is involved in the degeneration of RGCs induced by excitotoxicity, and that the interaction between NR2D and Dock3 may have a neuroprotective effect. These findings raise the possibility that NR2D and Dock3 might be potential therapeutic targets for treating neurodegenerative diseases such as Alzheimer&#8217;s disease and NTG.</description>
        <link>http://www.molecularbrain.com/content/6/1/22</link>
                <dc:creator>Ning Bai</dc:creator>
                <dc:creator>Hideki Hayashi</dc:creator>
                <dc:creator>Tomomi Aida</dc:creator>
                <dc:creator>Kazuhiko Namekata</dc:creator>
                <dc:creator>Takayuki Harada</dc:creator>
                <dc:creator>Masayoshi Mishina</dc:creator>
                <dc:creator>Kohichi Tanaka</dc:creator>
                <dc:source>Molecular Brain 2013, null:22</dc:source>
        <dc:date>2013-05-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6606-6-22</dc:identifier>
                                <prism:require>/content/figures/1756-6606-6-22-toc.gif</prism:require>
                <prism:publicationName>Molecular Brain</prism:publicationName>
        <prism:issn>1756-6606</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>22</prism:startingPage>
        <prism:publicationDate>2013-05-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularbrain.com/content/6/1/19">
        <title>A human Dravet syndrome model from patient induced pluripotent stem cells</title>
        <description>Background:
Dravet syndrome is a devastating infantile-onset epilepsy syndrome with cognitive deficits and autistic traits caused by genetic alterations in SCN1A gene encoding the &#945;-subunit of the voltage-gated sodium channel Nav1.1. Disease modeling using patient-derived induced pluripotent stem cells (iPSCs) can be a powerful tool to reproduce this syndrome&#8217;s human pathology. However, no such effort has been reported to date. We here report a cellular model for DS that utilizes patient-derived iPSCs.
Results:
We generated iPSCs from a Dravet syndrome patient with a c.4933C&gt;T substitution in SCN1A, which is predicted to result in truncation in the fourth homologous domain of the protein (p.R1645*). Neurons derived from these iPSCs were primarily GABAergic (&gt;50%), although glutamatergic neurons were observed as a minor population (&lt;1%). Current-clamp analyses revealed significant impairment in action potential generation when strong depolarizing currents were injected.
Conclusions:
Our results indicate a functional decline in Dravet neurons, especially in the GABAergic subtype, which supports previous findings in murine disease models, where loss-of-function in GABAergic inhibition appears to be a main driver in epileptogenesis. Our data indicate that patient-derived iPSCs may serve as a new and powerful research platform for genetic disorders, including the epilepsies.</description>
        <link>http://www.molecularbrain.com/content/6/1/19</link>
                <dc:creator>Norimichi Higurashi</dc:creator>
                <dc:creator>Taku Uchida</dc:creator>
                <dc:creator>Christoph Lossin</dc:creator>
                <dc:creator>Yoshio Misumi</dc:creator>
                <dc:creator>Yohei Okada</dc:creator>
                <dc:creator>Wado Akamatsu</dc:creator>
                <dc:creator>Yoichi Imaizumi</dc:creator>
                <dc:creator>Bo Zhang</dc:creator>
                <dc:creator>Kazuki Nabeshima</dc:creator>
                <dc:creator>Masayuki Mori</dc:creator>
                <dc:creator>Shutaro Katsurabayashi</dc:creator>
                <dc:creator>Yukiyoshi Shirasaka</dc:creator>
                <dc:creator>Hideyuki Okano</dc:creator>
                <dc:creator>Shinichi Hirose</dc:creator>
                <dc:source>Molecular Brain 2013, null:19</dc:source>
        <dc:date>2013-05-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6606-6-19</dc:identifier>
                            <dc:title>A new platform for investigating Dravet syndrome</dc:title>
                            <dc:description>&lt;p&gt;Induced pluripotent stem cells from the skin of patients with Dravet syndrome show Dravet-like functional impairment when they are converted into neurons, providing an unparalleled insight into the mechanism behind this rare form of infantile-onset epilepsy.&lt;/p&gt;</dc:description>
                <prism:require>/content/figures/1756-6606-6-19-toc.gif</prism:require>
                <prism:publicationName>Molecular Brain</prism:publicationName>
        <prism:issn>1756-6606</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>19</prism:startingPage>
        <prism:publicationDate>2013-05-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularbrain.com/content/6/1/21">
        <title>Regulation of epileptiform activity by two distinct subtypes of extrasynaptic GABAA receptors</title>
        <description>Background:
GABAergic deficit is one of the major mechanisms underlying epileptic seizures. Previous studies have mainly focused on alterations of synaptic GABAergic inhibition during epileptogenesis. Recent work suggested that tonic inhibition may also play a role in regulating epileptogenesis, but the underlying mechanism is not well understood.
Results:
We employed molecular and pharmacological tools to investigate the role of tonic inhibition during epileptogenesis both in vitro and in vivo. We overexpressed two distinct subtypes of extrasynaptic GABAA receptors, &#945;5&#946;3&#947;2 and &#945;6&#946;3&#948; receptors, in cultured hippocampal neurons. We demonstrated that overexpression of both &#945;5&#946;3&#947;2 and &#945;6&#946;3&#948; receptors enhanced tonic inhibition and reduced epileptiform activity in vitro. We then showed that injection of THIP (5 &#956;M), a selective agonist for extrasynaptic GABAA receptors at low concentration, into rat brain also suppressed epileptiform burst activity and behavioral seizures in vivo. Mechanistically, we discovered that low concentration of THIP had no effect on GABAergic synaptic transmission and did not affect the basal level of action potentials, but significantly inhibited high frequency neuronal activity induced by epileptogenic agents.
Conclusions:
Our studies suggest that extrasynaptic GABAA receptors play an important role in controlling hyperexcitatory activity, such as that during epileptogenesis, but a less prominent role in modulating a low level of basal activity. We propose that tonic inhibition may play a greater role under pathological conditions than in physiological conditions in terms of modulating neural network activity.</description>
        <link>http://www.molecularbrain.com/content/6/1/21</link>
                <dc:creator>Yajie Sun</dc:creator>
                <dc:creator>Zheng Wu</dc:creator>
                <dc:creator>Shuzhen Kong</dc:creator>
                <dc:creator>Dongyun Jiang</dc:creator>
                <dc:creator>Anar Pitre</dc:creator>
                <dc:creator>Yun Wang</dc:creator>
                <dc:creator>Gong Chen</dc:creator>
                <dc:source>Molecular Brain 2013, null:21</dc:source>
        <dc:date>2013-05-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6606-6-21</dc:identifier>
                                <prism:require>/content/figures/1756-6606-6-21-toc.gif</prism:require>
                <prism:publicationName>Molecular Brain</prism:publicationName>
        <prism:issn>1756-6606</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>21</prism:startingPage>
        <prism:publicationDate>2013-05-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularbrain.com/content/6/1/20">
        <title>Abnormal interneuron development in disrupted-in-schizophrenia-1 L100P mutant mice</title>
        <description>Background:
Interneuron deficits are one of the most consistent findings in post-mortem studies of schizophrenia patients and are likely important in the cognitive deficits associated with schizophrenia. Disrupted-in-Schizophrenia 1 (DISC1), a strong susceptibility gene for schizophrenia and other mental illnesses, is involved in neurodevelopment, including that of interneurons. However, the mechanism by which DISC1 regulates interneuron development remains unknown. In this study, we analyzed interneuron histology in the Disc1-L100P single point mutation mouse, that was previously shown to have behavioral abnormalities and cortical developmental defects related to schizophrenia.
Results:
We sought to determine whether a Disc1-L100P point mutation in the mouse would alter interneuron density and location. First, we examined interneuron position in the developing mouse cortex during embryonic days 14&#8211;16 as an indicator of interneuron tangential migration, and found striking migration deficits in Disc1-L100P mutants. Further analysis of adult brains revealed that the Disc1-L100P mutants have selective alterations of calbindin- and parvalbumin-expressing interneurons in the cortex and hippocampus, decreased GAD67/PV co-localization and mis-positioned interneurons across the neocortex when compared to wild-type littermates.
Conclusion:
Our results are consistent with the anomalies seen in post-mortem schizophrenia studies and other Disc1 mutant mouse models. Future research is required to determine the specific mechanisms underlying these cellular deficits. Overall, these findings provide further evidence that DISC1 participates in interneuron development and add to our understanding of how DISC1 variants can affect susceptibility to psychiatric illness.</description>
        <link>http://www.molecularbrain.com/content/6/1/20</link>
                <dc:creator>Frankie Lee</dc:creator>
                <dc:creator>Clement Zai</dc:creator>
                <dc:creator>Sabine Cordes</dc:creator>
                <dc:creator>John Roder</dc:creator>
                <dc:creator>Albert Wong</dc:creator>
                <dc:source>Molecular Brain 2013, null:20</dc:source>
        <dc:date>2013-04-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6606-6-20</dc:identifier>
                                <prism:require>/content/figures/1756-6606-6-20-toc.gif</prism:require>
                <prism:publicationName>Molecular Brain</prism:publicationName>
        <prism:issn>1756-6606</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>20</prism:startingPage>
        <prism:publicationDate>2013-04-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularbrain.com/content/6/1/18">
        <title>Neonatal dexamethasone treatment exacerbates hypoxic-ischemic brain injury</title>
        <description>Background:
The synthetic glucocorticoid dexamethasone (DEX) is commonly used to prevent chronic lung disease in prematurely born infants. Treatment regimens usually consist of high doses of DEX for several weeks, notably during a critical period of brain development. Therefore, there is some concern about adverse effects of this clinical practice on fetal brain development. In this study, using a clinically relevant rat model, we examined the impact of neonatal DEX treatment on subsequent brain injury due to an episode of cerebral hypoxia-ischemia (HI).
Results:
We found that a 3-day tapering course (0.5, 0.3 and 0.1 mg/kg) of DEX treatment in rat pups on postnatal days 1&#8211;3 (P1-3) exacerbated HI-induced brain injury on P7 by a glucocorticoid receptor-mediated mechanism. The aggravating effect of neonatal DEX treatment on HI-induced brain injury was correlated with decreased glutamate transporter-1 (GLT-1)-mediated glutamate reuptake. The expression levels of mRNA and protein of GLT-1 were significantly reduced by neonatal DEX treatment. We also found that the administration of &#946;-lactam antibiotic ceftriaxone increased GLT-1 protein expression and significantly reduced HI-induced brain injury in neonatal DEX-treated rats.
Conclusions:
These results suggest that early DEX exposure may lead the neonatal brain to be more vulnerable to subsequent HI injury, which can be ameliorated by administrating ceftriaxone.</description>
        <link>http://www.molecularbrain.com/content/6/1/18</link>
                <dc:creator>Kan-Hsun Chang</dc:creator>
                <dc:creator>Che-Ming Yeh</dc:creator>
                <dc:creator>Chia-Yu Yeh</dc:creator>
                <dc:creator>Chiung-Chun Huang</dc:creator>
                <dc:creator>Kuei-Sen Hsu</dc:creator>
                <dc:source>Molecular Brain 2013, null:18</dc:source>
        <dc:date>2013-04-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6606-6-18</dc:identifier>
                                <prism:require>/content/figures/1756-6606-6-18-toc.gif</prism:require>
                <prism:publicationName>Molecular Brain</prism:publicationName>
        <prism:issn>1756-6606</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>18</prism:startingPage>
        <prism:publicationDate>2013-04-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularbrain.com/content/6/1/17">
        <title>Consolidation of auditory fear memories formed by weak unconditioned stimuli requires NMDA receptor activation and de novo protein synthesis in the striatum</title>
        <description>Background:
Fear is one of the most potent emotional experiences and is an adaptive component of response to potentially threatening stimuli. Cumulative evidence suggests that the amygdala plays a central role in the acquisition, storage and expression of fear memory. We previously showed that the selective ablation of striatal neurons in the adult brain impairs the long-term, but not short-term, memory for auditory fear conditioning with a lower-intensity footshock. This finding raises an intriguing possibility that long-term auditory fear memory may be consolidated in the striatum.
Results:
There was a significant difference in the freezing responses between two groups of mice subjected to paired and unpaired conditioning, indicating that the auditory fear conditioning with a lower-intensity footshock is an associative learning. Post-conditioning infusion of NMDA receptor inhibitors into the striatum suppressed the consolidation of auditory fear memory when mice were conditioned with a low-intensity footshock. Furthermore, intra-striatum infusion of protein synthesis blocker anisomycin immediately or 1&#8201;h after the conditioning prevented the formation of auditory fear memory. On the other hand, the infusion of anisomycin 3&#8201;h after conditioning exerted little effect on the auditory fear conditioning, consistent with the presence of a critical time window of protein synthesis for memory consolidation.
Conclusions:
These results suggest that NMDA receptors and de novo protein synthesis in the striatum are crucial for the consolidation of auditory fear memory formed with a low-intensity unconditioned stimulus.</description>
        <link>http://www.molecularbrain.com/content/6/1/17</link>
                <dc:creator>Ayumi Kishioka</dc:creator>
                <dc:creator>Takeshi Uemura</dc:creator>
                <dc:creator>Fumiaki Fukushima</dc:creator>
                <dc:creator>Masayoshi Mishina</dc:creator>
                <dc:source>Molecular Brain 2013, null:17</dc:source>
        <dc:date>2013-04-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6606-6-17</dc:identifier>
                                <prism:require>/content/figures/1756-6606-6-17-toc.gif</prism:require>
                <prism:publicationName>Molecular Brain</prism:publicationName>
        <prism:issn>1756-6606</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>17</prism:startingPage>
        <prism:publicationDate>2013-04-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularbrain.com/content/6/1/16">
        <title>Roles of vitamin D in amyotrophic lateral sclerosis: possible genetic and cellular signaling mechanisms</title>
        <description>Evidence suggests that there are aberrations in the vitamin D-endocrine system in subjects with amyotrophic lateral sclerosis (ALS). Here, we review the relationship between vitamin D and ALS. Vitamin D deficiency was reported in patients with ALS. Dietary vitamin D3 supplementation improves functional capacity in the G93A transgenic mouse model of ALS. Genetic studies have provided an opportunity to identify the proteins that link vitamin D to ALS pathology, including major histocompatibility complex (MHC) class II molecules, toll-like receptors, poly(ADP-ribose) polymerase-1, heme oxygenase-1, and calcium-binding proteins, as well as the reduced form of nicotinamide adenine dinucleotide phosphate. Vitamin D also exerts its effect on ALS through cell-signaling mechanisms, including glutamate, matrix metalloproteinases, mitogen-activated protein kinase pathways, the Wnt/&#946;-catenin signaling pathway, prostaglandins, reactive oxygen species, and nitric oxide synthase.In conclusion, vitamin D may have a role in ALS. Further investigation of vitamin D in ALS patients is needed.</description>
        <link>http://www.molecularbrain.com/content/6/1/16</link>
                <dc:creator>Khanh vinh qu¿c L¿¿ng</dc:creator>
                <dc:creator>Lan Thi Hoàng Nguy¿n</dc:creator>
                <dc:source>Molecular Brain 2013, null:16</dc:source>
        <dc:date>2013-04-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6606-6-16</dc:identifier>
                                <prism:require>/content/figures/1756-6606-6-16-toc.gif</prism:require>
                <prism:publicationName>Molecular Brain</prism:publicationName>
        <prism:issn>1756-6606</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>16</prism:startingPage>
        <prism:publicationDate>2013-04-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularbrain.com/content/6/1/15">
        <title>Fragile X mental retardation protein and synaptic plasticity</title>
        <description>Loss of the translational repressor FMRP causes Fragile X syndrome. In healthy neurons, FMRP modulates the local translation of numerous synaptic proteins. Synthesis of these proteins is required for the maintenance and regulation of long-lasting changes in synaptic strength. In this role as a translational inhibitor, FMRP exerts profound effects on synaptic plasticity.</description>
        <link>http://www.molecularbrain.com/content/6/1/15</link>
                <dc:creator>Michael Sidorov</dc:creator>
                <dc:creator>Benjamin Auerbach</dc:creator>
                <dc:creator>Mark Bear</dc:creator>
                <dc:source>Molecular Brain 2013, null:15</dc:source>
        <dc:date>2013-04-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6606-6-15</dc:identifier>
                                <prism:require>/content/figures/1756-6606-6-15-toc.gif</prism:require>
                <prism:publicationName>Molecular Brain</prism:publicationName>
        <prism:issn>1756-6606</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>15</prism:startingPage>
        <prism:publicationDate>2013-04-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
